What causes mixed-field agglutination encountered in ABO (Anti-B and Anti-A) forward grouping?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 17, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Causes of Mixed-Field Agglutination in ABO Forward Grouping

Cold reactive autoagglutinins are the most common cause of mixed-field agglutination encountered in ABO forward grouping. This pattern can be misleading and must be carefully distinguished from other causes to ensure accurate blood typing.

Primary Causes of Mixed-Field Agglutination

Cold Reactive Autoagglutinins

  • Cold reactive autoagglutinins cause red cells to spontaneously agglutinate at lower temperatures, creating a mixed-field pattern when testing with anti-A and anti-B reagents 1
  • These antibodies react with red cell antigens at room temperature or below, causing some cells to clump while others remain free in suspension
  • This creates the characteristic mixed-field appearance in the reaction tube or column agglutination test

Other Important Causes

  1. A3 Subgroup

    • While A3 subgroup has traditionally been associated with mixed-field agglutination, research shows this is not always the case
    • Mixed-field agglutination observed in column agglutination testing (CAT) may be incorrectly attributed to A3 subgroup 1
    • PCR-sequence-based typing has shown that many cases presumed to be A3 are actually other ABO variants
  2. Chimerism

    • Dispermic chimerism (fusion of two different zygotes) can present with mixed-field agglutination during routine ABO typing 2, 3
    • These individuals have two distinct cell populations with different ABO types
    • Can be confirmed through genetic testing showing multiple alleles at various loci
  3. Hematological Disorders

    • Patients with acute myeloid leukemia and other malignant hemopathies may show mixed-field agglutination 4
    • This occurs due to decreased activity of A or B glycosyltransferases in affected red cell populations
    • The enzyme activity is reduced in cell subpopulations that have lost A or B antigens
  4. Polyagglutination

    • Bacterial infections or certain hematological diseases can expose normally hidden red cell antigens (cryptoantigens) 5
    • Most normal sera contain natural antibodies to these antigens, causing widespread agglutination
    • This can create apparent discrepancies in ABO typing and mixed-field patterns

Diagnostic Approach

When mixed-field agglutination is observed:

  1. Repeat testing using both column agglutination and tube methods with different antibody clones
  2. Perform testing at different temperatures to identify cold-reactive antibodies
  3. Consider molecular testing (PCR-SBT of ABO gene) if subgroup is suspected
  4. Evaluate patient for underlying conditions:
    • Recent infections
    • Hematological disorders
    • History of transplantation
    • Twin pregnancy or chimeric possibility

Clinical Significance

  • Mixed-field agglutination can lead to ABO typing discrepancies and potential transfusion complications if misinterpreted
  • Proper identification of the underlying cause is essential for accurate blood typing
  • In cases where cold autoagglutinins are suspected, warming the sample to 37°C before testing may help resolve the issue

Mixed-field agglutination is not typically caused by abnormal concentrations of serum proteins, Para-Bombay phenotype, or decreasing Rh type. The pattern requires thorough investigation to determine its true etiology, with cold-reactive autoagglutinins being the most common culprit in routine blood banking practice.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.